Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 2
1976 1
1977 1
1978 1
1979 2
1980 1
1981 1
1982 2
1983 2
1984 1
1985 1
1986 1
1988 1
1989 1
1990 1
1991 4
1992 5
1993 3
1994 3
1995 1
1996 5
1997 2
1998 2
1999 3
2001 2
2002 4
2003 1
2004 1
2006 1
2007 1
2008 1
2009 1
2010 1
2011 1
2012 1
2013 1
2014 1
2015 3
2016 4
2018 1
2019 1
2021 3
2022 2
2023 2

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis.
Elia AE, Lalli S, Monsurrò MR, Sagnelli A, Taiello AC, Reggiori B, La Bella V, Tedeschi G, Albanese A. Elia AE, et al. Eur J Neurol. 2016 Jan;23(1):45-52. doi: 10.1111/ene.12664. Epub 2015 Feb 9. Eur J Neurol. 2016. PMID: 25664595 Free PMC article. Clinical Trial.
BACKGROUND AND PURPOSE: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. ...Secondary outcomes included between-treatment comparison of ALSFRS-R at study end, com …
BACKGROUND AND PURPOSE: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used fo …
Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial.
Ahmad Z, Subramanyam L, Szczepaniak L, Simha V, Adams-Huet B, Garg A. Ahmad Z, et al. Eur J Endocrinol. 2013 Apr 15;168(5):771-8. doi: 10.1530/EJE-12-0969. Print 2013 May. Eur J Endocrinol. 2013. PMID: 23447519 Free PMC article. Clinical Trial.
There is no proven effective therapy for hepatic steatosis, but cholic acid (CA), a farnesoid X receptor agonist, has previously been shown to reduce hepatic triglyceride (TG) content in mice and serum TG in humans. ...
There is no proven effective therapy for hepatic steatosis, but cholic acid (CA), a farnesoid X receptor agonist, has previous …
Cholic acid and ursodeoxycholic acid therapy in primary biliary cirrhosis. Changes in bile acid patterns and their correlation with liver function.
Güldütuna S, Leuschner M, Wunderlich N, Nickel A, Bhatti S, Hübner K, Leuschner U. Güldütuna S, et al. Eur J Clin Pharmacol. 1993;45(3):221-5. doi: 10.1007/BF00315387. Eur J Clin Pharmacol. 1993. PMID: 8276045 Clinical Trial.
We treated 6 patients with Stage II primary biliary cirrhosis with cholic acid (CA) 10 mg.kg-1 per day for 3 months and then with the same dose of ursodeoxycholic acid (UDCA). ...No changes in liver function tests or bile acid metabolism were found in …
We treated 6 patients with Stage II primary biliary cirrhosis with cholic acid (CA) 10 mg.kg-1 per day for 3 months and then w …
Effect of simvastatin, ursodeoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in nonfamilial hypercholesterolemia.
Mazzella G, Parini P, Festi D, Bazzoli F, Aldini R, Roda A, Tonelli D, Cipolla A, Salzetta A, Roda E. Mazzella G, et al. Hepatology. 1992 Jun;15(6):1072-8. doi: 10.1002/hep.1840150617. Hepatology. 1992. PMID: 1592346 Clinical Trial.
It has been recently shown that the newest hypocholesterolemic agent, simvastatin, lowers the biliary cholesterol saturation index and that its association with ursodeoxycholic acid renders it more effective. To determine the mechanism by which simvastatin decreases the bi …
It has been recently shown that the newest hypocholesterolemic agent, simvastatin, lowers the biliary cholesterol saturation index and that …
Bile acid metabolites in early pregnancy and risk of gestational diabetes mellitus: Results from a prospective cohort study.
Wu Y, Wang Z, Zhao Z, Song X, Miao M, Zhang X. Wu Y, et al. Diabetes Obes Metab. 2023 Aug;25(8):2255-2267. doi: 10.1111/dom.15104. Epub 2023 May 10. Diabetes Obes Metab. 2023. PMID: 37161712
Using logistic and cubic spline models, we examined associations between baseline plasma bile acid metabolites and GDM risk during mid-late pregnancy. A meta-analysis of prospective studies of bile acid and GDM risk was performed. RESULTS: The linear and nonlinear u …
Using logistic and cubic spline models, we examined associations between baseline plasma bile acid metabolites and GDM risk during mi …
Metabolomic Changes Upon Conjugated Linoleic Acid Supplementation and Predictions of Body Composition Responsiveness.
He Y, Xu K, Li Y, Chang H, Liao X, Yu H, Tian T, Li C, Shen Y, Wu Q, Liu X, Shi L. He Y, et al. J Clin Endocrinol Metab. 2022 Aug 18;107(9):2606-2615. doi: 10.1210/clinem/dgac367. J Clin Endocrinol Metab. 2022. PMID: 35704027 Clinical Trial.

CONTEXT: Conjugated linoleic acid (CLA) may optimize body composition, yet mechanisms underlining its benefits are not clear in humans. ...RESULTS: Compared with placebo, CLA altered 57 metabolites (P < 0.10) enriched in lipids/lipid-like molecules including glycerophos

…
CONTEXT: Conjugated linoleic acid (CLA) may optimize body composition, yet mechanisms underlining its benefits are not clear in human …
Effect of primary bile acid ingestion on bile acid metabolism and biliary lipid secretion in gallstone patients.
LaRusso NF, Hoffman NE, Hofmann AF, Northfield TC, Thistle JL. LaRusso NF, et al. Gastroenterology. 1975 Dec;69(6):1301-14. Gastroenterology. 1975. PMID: 1193329 Clinical Trial.
Total bile acid pool size doubled in half the patients receiving either bile acid and was not different during treatment with chenic or cholic acid. Compared to cholic acid, chenic acid caused decreased cholesterol output with no d …
Total bile acid pool size doubled in half the patients receiving either bile acid and was not different during treatment with …
Feedback regulation of bile acid synthesis measured by stable isotope kinetics in humans.
Tauber G, Empen K, Scheibner J, Fuchs M, Stange EF. Tauber G, et al. Eur J Gastroenterol Hepatol. 1996 Jan;8(1):23-31. doi: 10.1097/00042737-199601000-00006. Eur J Gastroenterol Hepatol. 1996. PMID: 8900905 Clinical Trial.
RESULTS: Administration of cholic acid nearly doubled the input and pool of deoxycholic acid; chenodeoxycholic acid synthesis was inhibited by 38% and pool size was reduced by 50%. ...Oral chenodeoxycholic acid resulted in an inhibition of ch …
RESULTS: Administration of cholic acid nearly doubled the input and pool of deoxycholic acid; chenodeoxycholic acid …
Association between Circulating Vitamin D Metabolites and Fecal Bile Acid Concentrations.
Jacobs ET, Haussler MR, Alberts DS, Kohler LN, Lance P, Martínez ME, Roe DJ, Jurutka PW. Jacobs ET, et al. Cancer Prev Res (Phila). 2016 Jul;9(7):589-97. doi: 10.1158/1940-6207.CAPR-16-0033. Epub 2016 May 2. Cancer Prev Res (Phila). 2016. PMID: 27138789 Free PMC article. Clinical Trial.
After adjustment for age, sex, BMI, physical activity, and calcium intake, adequate concentrations of 25(OH)D (30 ng/mL) were statistically significantly associated with reduced odds for high levels of total [OR, 0.61; 95% confidence interval (CI), 0.38-0.97], and primary (OR, 0. …
After adjustment for age, sex, BMI, physical activity, and calcium intake, adequate concentrations of 25(OH)D (30 ng/mL) were statistically …
Fish oil increases bile acid synthesis in male patients with hypertriglyceridemia.
Jonkers IJ, Smelt AH, Princen HM, Kuipers F, Romijn JA, Boverhof R, Masclee AA, Stellaard F. Jonkers IJ, et al. J Nutr. 2006 Apr;136(4):987-91. doi: 10.1093/jn/136.4.987. J Nutr. 2006. PMID: 16549462 Free article. Clinical Trial.
Compared with baseline, bezafibrate therapy was associated with reduced cholesterol synthesis (-25%, P = 0.009) without changes in bile acid synthesis rate and pool size. In contrast, fish oil increased bile acid synthesis (+31% vs. baseline, P = 0.07 and +53% vs. b …
Compared with baseline, bezafibrate therapy was associated with reduced cholesterol synthesis (-25%, P = 0.009) without changes in bile a …
77 results

Searches related to "cholic acid"